Trial Profile
A Phase III Trial of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With or Resistant to an Anthracycline and Who Are Taxane Resistant.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Jan 2022
Price :
$35
*
At a glance
- Drugs Vinflunine (Primary) ; Capecitabine
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors Pierre Fabre
- 12 Oct 2014 According to UKCRN record, planned number of patients reported as 764.
- 11 Jun 2014 Planned End Date changed from 1 Apr 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov record.
- 03 Jun 2014 Primary endpoint 'Progression-free-survival' has been met.